Literature DB >> 24916693

TP53 mutations and lung cancer: not all mutations are created equal.

Ramaswamy Govindan1, Jason Weber2.   

Abstract

Mutations in TP53 are common in non-small cell lung cancer. Apart from the loss of tumor-suppressor functions, TP53 mutations may result in gain of function favoring cellular proliferation, inhibition of apoptosis, and genomic instability. Some TP53 mutations are more likely to affect the course of the disease than others. ©2014 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24916693     DOI： 10.1158/1078-0432.CCR-14-0899

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  9 in total

1.  Potential lung carcinogenicity induced by chronic exposure to PM2.5 in the rat.

Authors:  Xiaoli Hu; Qingzhao Li; Shifeng Shao; Qiang Zeng; Shoufang Jiang; Qi Wu; Chunyang Jiang
Journal:  Environ Sci Pollut Res Int       Date:  2017-06-28       Impact factor: 4.223

Review 2.  Clinical Outcomes of TP53 Mutations in Cancers.

Authors:  Ana I Robles; Jin Jen; Curtis C Harris
Journal:  Cold Spring Harb Perspect Med       Date:  2016-09-01       Impact factor: 6.915

3.  Comprehensive profiling and quantitation of oncogenic mutations in non small-cell lung carcinoma using single molecule amplification and re-sequencing technology.

Authors:  Shirong Zhang; Bing Xia; Hong Jiang; Limin Wang; Rujun Xu; Yanbin Shi; Jianguang Zhang; Mengnan Xu; David S Cram; Shenglin Ma
Journal:  Oncotarget       Date:  2016-08-02

4.  Cathepsin L activated by mutant p53 and Egr-1 promotes ionizing radiation-induced EMT in human NSCLC.

Authors:  Wenjuan Wang; Yajie Xiong; Xinyuan Ding; Long Wang; Yifan Zhao; Yao Fei; Ying Zhu; Xiao Shen; Caihong Tan; Zhongqin Liang
Journal:  J Exp Clin Cancer Res       Date:  2019-02-07

5.  Concomitant TP53 mutations with response to crizotinib treatment in patients with ALK-rearranged non-small-cell lung cancer.

Authors:  Peng Song; Fanshuang Zhang; Yan Li; Guangjian Yang; Wenbin Li; Jianming Ying; Shugeng Gao
Journal:  Cancer Med       Date:  2019-03-07       Impact factor: 4.452

6.  Mutant p53 achieved Gain-of-Function by promoting tumor growth and immune escape through PHLPP2/AKT/PD-L1 pathway.

Authors:  Nannan Liu; Xinxiu Jiang; Leiming Guo; Chuchu Zhang; Meimei Jiang; Zhuoran Sun; Yizheng Zhang; Wunan Mi; Jiehan Li; Yang Fu; Feng Wang; Lingling Zhang; Yingjie Zhang
Journal:  Int J Biol Sci       Date:  2022-03-14       Impact factor: 6.580

7.  Repeated PM2.5 exposure inhibits BEAS-2B cell P53 expression through ROS-Akt-DNMT3B pathway-mediated promoter hypermethylation.

Authors:  Wei Zhou; Dongdong Tian; Jun He; Yimei Wang; Lijun Zhang; Lan Cui; Li Jia; Li Zhang; Lizhong Li; Yulei Shu; Shouzhong Yu; Jun Zhao; Xiaoyan Yuan; Shuangqing Peng
Journal:  Oncotarget       Date:  2016-04-12

8.  Correlation between Gene Variants, Signaling Pathways, and Efficacy of Chemotherapy Drugs against Colon Cancers.

Authors:  Swarnendu Tripathi; Louiza Belkacemi; Margaret S Cheung; Rathindra N Bose
Journal:  Cancer Inform       Date:  2016-01-20

9.  Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer.

Authors:  A Kron; C Alidousty; M Scheffler; S Merkelbach-Bruse; D Seidel; R Riedel; M A Ihle; S Michels; L Nogova; J Fassunke; C Heydt; F Kron; F Ueckeroth; M Serke; S Krüger; C Grohe; D Koschel; J Benedikter; B Kaminsky; B Schaaf; J Braess; M Sebastian; K-O Kambartel; R Thomas; T Zander; A M Schultheis; R Büttner; J Wolf
Journal:  Ann Oncol       Date:  2018-10-01       Impact factor: 32.976
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.